See related article at Key points In this issue’s research article, Rebić and colleagues show that rates of opioid prescribing across 6 Canadian provinces declined gradually from 2018 to 2022, with n ...

This 3-part series looks at the current evidence for the treatment of SUD, alcohol use disorder, and tobacco use disorder.

– Positive results from ALLEVIATE-1 Phase 3 pivotal trial for cebranopadol which demonstrates statistically significant pain reduction compared to placebo in patients after abdominoplasty will be ...

Mira Pharmaceuticals MIRA stock jumped 70% after-hours on preclinical data showing Mira-55 outperformed morphine in pain relief and inflammation reduction.

THURSDAY, Oct. 9, 2025 (HealthDay News) — A widely prescribed opioid painkiller is not all it’s cracked up to be, a new evidence review has concluded. The opioid painkiller tramadol does little to ...

Studies combing through past patient data have made a similar link between drugs like Ozempic and a loss of appetite for more than just food.

Shares of Mira Pharmaceuticals surged 70% after-hours on Wednesday after the company announced new preclinical data showing ...

Deciphering how the GR forms oligomers—through the binding of several subunits—opens a crucial avenue for developing more ...

Using psychedelics to treat psychiatric diseases has become less controversial as scientists continue to reveal their ...

A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical Technology, has discovered the critical mechanism of action of tetrandrine, a ...

Drugs to treat inflammatory and autoimmune diseases - such as asthma, psoriasis, rheumatoid arthritis or Chrousos syndrome - ...